

1 Analysis of anti-Omicron neutralizing antibody titers in plasma from pre-Omicron convalescents and 2 vaccinees.

3

4 Daniele Focosi^{1, #}, Massimo Franchini², Michael J. Joyner³, Arturo Casadevall⁴, David J Sullivan⁴

5

6 ¹North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

7 .

8 ²Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy; [massimo.franchini@asst-](mailto:massimo.franchini@asst-mantova.it)
9 [mantova.it](mailto:massimo.franchini@asst-mantova.it)

10 ³Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA
11 joyner.michael@mayo.edu ;

12 ⁴Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, MD
13 21218, USA; acasade1@jhu.edu #corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail:
14 daniele.focosi@gmail.com .

15

16 **Keywords:** COVID19; Omicron; convalescent plasma; vaccine; neutralizing antibodies.

17 **Word count:** abstract 210; body 2979.

18 **Acknowledgements:** none.

19 **Funding Information:** The analysis was supported by the U.S. Department of Defense's Joint Program
20 Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in
21 collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (D.S), with
22 additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health
23 (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1) (A.C).

24 **Author contributions:** D.F. and M.J.J. conceived the manuscript; D.F., D.J.S. and M.F. analyzed the
25 literature, curated tables and wrote manuscripts; M.F. provided Figure 1; D.S. provided Figures 2 -4. A.C.
26 and M.J.J. revised the manuscript.

27

28 Abstract

29 The novel SARS-CoV-2 Omicron, with its antigenic escape from unboosted vaccines and therapeutic
 30 monoclonal antibodies, demonstrates the continued relevance of COVID19 convalescent plasma (CCP)
 31 therapies. Lessons learnt from previous usage of CCP suggests focusing on outpatients and
 32 immunocompromised recipients, with high nAb-titer units. In this analysis we systematically reviewed
 33 Omicron neutralizing plasma activity data from 31 publications, and found that approximately 50%
 34 (426/841) of CCP from unvaccinated donors neutralizes Omicron with very low mean neutralization titers
 35 (about 30), representing a more than 30-fold reduction from paired WA-1 neutralization. Two doses of
 36 mRNA vaccines had a similar 50% percent neutralization with more than doubling of Omicron
 37 neutralization mean titer (about 60). However, CCP from vaccinees recovered from previous variants of
 38 concern or third-dose uninfected vaccinees was nearly 100% neutralizing with mean Omicron neutralizing
 39 titers over 1000, a 30-fold Omicron neutralizing antibody increase compared to non-boosted vaccinees or
 40 unvaccinated convalescents. These findings have implications for both CCP stocks collected in prior
 41 pandemic periods and plans to restart CCP collections. Plasma from either boosted vaccinees or
 42 vaccination after pre-Omicron COVID-19 has nearly 100% neutralizing activity with Omicron neutralizing
 43 levels similar to matched convalescent plasma to variant neutralizing activity. Thus, CCP provides an
 44 effective tool to combat the emergence of variants that defeat therapeutic monoclonal antibodies.

Introduction

The SARS-CoV-2 Omicron variant of concern (VOC) (named VUI-21NOV-01 by Public Health England and belonging to GISAID clade GR/484A) was first reported on November 8, 2021 in South Africa (particularly in Gauteng, North West and Limpopo regions, where it was likely to have been circulating for weeks¹), and shortly thereafter spread all around the world. Omicron mutations impact 27% of T cell epitopes² and 31% of B cell epitopes of Spike, while percentages for other VOC were significantly lower³. The Omicron variant already includes several sublineages (with more expected soon during such a massive spread), which are named by PANGO phylogeny using the BA alias: the BA.1 wave of Winter 2021-2022 has been suddenly replaced by BA.2 worldwide, with further BA.4 and BA.5 waves emerging in South Africa, BA.2.12.1 in USA, and the BA.1/BA.2 recombinant XE causing concern in UK.

The novel VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are delivered) and is initiating an unexpected boost in COVID19 convalescent plasma (CCP) usage, with Omicron being treated as a shifted novel virus instead of a SARS-CoV-2 variant drift. Two years into the pandemics, we are back to the starting line for some therapeutic agents. Specifically, Omicron escapes viral neutralization by most monoclonal antibodies (mAbs) authorized to date⁴⁻⁹ with the lone exception of bebtelovimab. Despite the development of promising oral small-chemical antivirals (molnupiravir and nirmatrelvir), the logistical and economical hurdles for deploying these drugs worldwide will prevent their immediate and widespread availability, and concerns remain regarding both molnupiravir (both safety¹⁰ and efficacy¹¹) and nirmatrelvir (efficacy¹²). COVID19 convalescent plasma (CCP) was used as a frontline treatment from the very beginning of the pandemic. Efficacy outcomes have been mixed to date, with most failures explained by low dose, late usage, or both¹³, but efficacy of high-titer CCP has been definitively proven in outpatients with mild disease stages^{14,15}. Neutralizing antibody (nAb) efficacy against VOC remains a prerequisite to support CCP usage, which can now be collected from vaccinated convalescents including donors recovered from breakthrough infections¹⁶: pre-Omicron evidence suggest that those nAbs have higher titers and are more effective against VOCs than those from unvaccinated convalescents^{17,18},

There are up to 48 different possible vaccine schedules according to EMA and FDA approvals including a number of homologous or heterologous boosts, but the most commonly delivered schedules in the western hemisphere are: 1) BNT162b2 or mRNA-1273 for 2 doses eventually followed by a homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost; 3) Ad26.COV2.S for 1 dose eventually followed by a BNT162b2 boost. Many more inactivated vaccines have been in use in low-and-middle income countries (LMIC), which are target regions for CCP therapy given that the minimal burden to expand the existing transfusion infrastructure to treat COVID-19. Most blood donors there have already received the vaccine schedule before, after or without having been infected, with an nAb titer generally declining over months. Hence identifying the settings where the nAb titer is highest will definitively increase the efficacy of CCP collections. Variations in nAb titers against a given SARS-CoV-2 strain are usually reported as fold-changes in geometric mean titer (GMT) compared to wild-type strains: nevertheless, fold-changes for groups that include non-responders can lead to highly artificial results and possibly over-interpretation. Rigorous studies have hence reported the percentage of responders as primary outcome and provided fold-changes of GMT where calculation is reasonable (100% responders in both arms)¹⁹.

To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford University Coronavirus Antiviral & Resistance Database, but as of April 30, 2022 the tables there summarizing “Virus Variants and Spike Mutations vs Convalescent Plasma” (<https://covdb.stanford.edu/page/susceptibility-data/#:~:text=Table%202.-,Virus%20Variants%20and%20Spike%20Mutations%20vs%20Convalescent%20Plasma,-Table%203.%20Virus>) and “Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons” (<https://covdb.stanford.edu/page/susceptibility-data/#table.2.virus.variants.and.spike.mutations.vs.convalescent.plasma>) report aggregate data from only 6 studies, and do not dissect the infecting sublineages, nor the different heterologous or homologous vaccination schemes, nor the time from infection/vaccine to neutralization assay. Consequently, a more in-depth analysis is needed to better stratify the populations.

98

99 Methods

On April 30, 2022, we searched PubMed, medRxiv and bioRxiv for research investigating the efficacy of CCP (either from vaccinated or unvaccinated donors) against SARS-CoV-2 VOC Omicron. In unvaccinated patients, convalescence was annotated according to infecting sublineage (pre-VOC Alpha, VOC Alpha, VOC Beta or VOC Delta). Given the heterologous immunity that develops after vaccination in convalescents, the infecting lineage was not annotated in vaccine recipients. In vaccinees, strata were created for 2 homologous doses, 3 homologous doses, or post-COVID-19 and post-vaccination (Vax-CCP). The mean neutralizing titer for WA-1 (pre-Alpha wild-type), Omicron and number out of total that neutralized Omicron was abstracted from studies.

Statistical significance between means was investigated using Tukey’s test.

109

110 Results

Our literature search identified 31 studies, that were then manually mined for relevant details and the PRISMA flowchart for our study is provided in Figure 1. Given the urgency to assess efficacy against the upcoming VOC Omicron, most studies (with a few exceptions) relied on Omicron pseudovirus neutralization assays, which, as opposed to live authentic virus, are scalable, do not require BSL-3 facilities, and provide results in less than 1 week. Geometric mean titer (GMT) of nAb and fold-reduction (FR) in GMT against Omicron compared to WA-1 were the most common ways of reporting changes.

Neutralizing activity to WA-1 from CCP collected from subjects infected with Alpha VOC, Delta VOC or vaccinated with 2 mRNA vaccine doses averaged nAb titers of 850 to 2,000 (Figure 2 and Table 1). Beta VOC CCP was tested in a few samples and averaged a nAb titer of 186. The same CCP averaged about a 30-FR against Omicron compared to WA-1. CCP from uninfected vaccinees receiving a third boost registered GMT averaging 10,000-20,000, or 10- fold higher dilutional nAb titer to WA-1 viral assays. The nAb FR against Omicron was now 10 to 20, but importantly the average nAb GMT was close to 1,000 again. The approximately 30-FR in nAb GMT from WA-1 to Omicron was reversed by the 30-fold increase in nAb GMT from either boosted vaccination or vaccination and COVID-19 combination.

In addition to the nAb GMT levels showing potency, the percentage of individuals within a study cohort positive for any level of Omicron neutralization shows the likelihood of a possible donation having anti-Omicron activity. All studies but one tested a limited number of 20 to 40 individuals. The pre-Alpha CCP showed that most (18 of 27 studies) had less than 50% of individuals tested within a study with measurable Omicron neutralizing activity: only 2 out of 27 studies indicated 100% of individuals tested showed Omicron neutralization (Figure 3). Likewise, most of the studies investigating Alpha and Beta CCP showed similar percent with nAb. Delta CCP had 6 of 7 studies with more than 50% Omicron neutralization. The plasma from studies of the 2-dose mRNA vaccines indicated a more uniform distributive increase in percent of individual patients with measurable Omicron nAb's. The stark contrast is post COVID-19/post vaccination (Vax-CCP), where 16 of 19 studies had 100% of individuals tested with anti-Omicron nAb. The 3-dose vaccinee studies had similarly had 12 of 17 studies with 100% measurable nAb.

There were 5 studies which directly compared anti-Omicron nAb titers in nonvaccinated pre-Alpha, Alpha, Beta, and Delta CCP, and vaccinated plasma with the same nAb assay (Figure 4). nAb GMT against WA-1 was higher for Alpha and Delta CCP but lower for Beta CCP. nAb GMT against Omicron was actually highest for Beta CCP with average levels of 14 for pre-Alpha, Alpha and Delta. In these 5 studies, nAb GMT rose from 2-dose vaccinations to post COVID-19 and post vaccination (VaxCCP) to the 3-dose boosted vaccination. Importantly, for nAb GMT against Omicron were 15 to 140 to 463, respectively representing a 10 to 30-fold rise.

Another set of 9 matched vaccination studies inclusive of plasma collected after 2 and 3 dose schedules, as well as post COVID-19 and post vaccination plasma (Vax-CCP) depicted a 60-fold rise in GMT of anti-Omicron nAb from the 2-dose vaccine to post COVID-19 vaccinees, and a 30-fold increase after the third vaccine dose. The pattern was similar for nAb GMT against WA-1.

The AZD1222, 3-dose mRNA-1273 and Ad26.COVS2 vaccines were understudied, with 3 or less independent studies at different time points, reported in Table 10. The GMT nAb to Omicron after 3-mRNA-1273 doses ranged 60 to 2000, with a 5 to 15 FR compared with WA-1. nAb to Omicron GMT after AZD1222 vaccine was modest (~10 to 20), as with Ad26.COVS2 vaccine (~20 to 40). Two studies reported on post-COVID-19/post-mRNA-1273 with nAb GMT against Omicron of 38 and 272. Studies with 100% of individual patient samples neutralizing Omicron included 2 3-dose mRNA-1273 studies, one AZD1222 study, and one post-COVID-19/post-mRNA-1273 study.

Few data exist for comparisons among different vaccine boosts. For CoronaVac® (SinoVac), three doses led to 5.1 FR in nAb titer²⁰, while for Sputnik V nAb titer moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3 months after a boost with Sputnik Light^{21,22}. These *in vitro* findings have been largely confirmed *in vivo*, where prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination, protects against Omicron re-infection²³.

The studies included here mostly refer to neutralization of Omicron BA.1 sublineage from CCP collected from convalescent patients from pre-Omicron VOCs. A small study nevertheless confirmed that CCP from patients infected by wild-type SARS-CoV-2 or recipients of current mRNA vaccines showed a substantial loss in neutralizing activity that was comparable against BA.1, BA.1.1 and BA.2²⁴, but was rescued against BA.2 by vaccine boosts²⁵. Furthermore, within-Omicron CCP efficacy (i.e., efficacy of CCP collected from

convalescents of an Omicron sublineage against the same or another Omicron sublineage) has been investigated in a few publications so far:

- BA.1 CCP against BA.1: BA.1 breakthrough infection in fully vaccinated individuals rapidly elicited potent cross-reactive broad nAbs against VOCs Alpha, Beta, Gamma, Delta and BA.1, from unmeasurable IC₅₀ values to mean 1:2929 at around 9-12 days, which were higher than the mean peak IC₅₀ values of BNT162b2 vaccinees^{26,27}. Convalescent serums only displayed low level of neutralization activity against the cognate virus and were unable to neutralize other SARS-CoV-2 variants²⁸.
- BA.1 CCP against BA.2: 3 studies on 7 Omicron BA.1 breakthrough infections showed that the neutralization of the BA.2 sublineage was 1.3 to 1.8-fold lower than against the parental BA.1 sublineage^{24,29,30}. The neutralizing GMTs against heterologous BA.2 and USA/WA1-2020 were 4.2- and 28.4-fold lower than the GMT against homologous BA.1, respectively³¹. Accordingly, antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1 and BA.2 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity³².
 - BA.1 CCP against BA.2.12.1 : compared to BA.2, BA.2.12.1 exhibits stronger neutralization escape from the plasma of 3-dose vaccinees and from vaccinated BA.1 convalescents.³³.
- BA.1 CCP against BA.4/BA.5: in 24 Omicron/BA.1 infected but unvaccinated individuals, FRNT₅₀ declined from 275 for BA.1 to 36 for BA.4 and 37 for BA.5, a 7.6 and 7.5-FR, respectively. In 15 BNT162b2- or Ad26.CoV.2S-vaccinated with breakthrough Omicron/BA.1 infection, FRNT₅₀ declined from 507 for BA.1 to 158 for BA.4 (3.2-fold) and 198 for BA.5 (2.6-fold). Absolute BA.4 and BA.5 neutralization levels were about 5-fold higher in this group versus unvaccinated BA.1-infected participants³⁴. Compared to BA.2, BA.4/BA.5 exhibited stronger neutralization escape from the plasma of 3-dose vaccinees and from vaccinated BA.1 convalescents.³³.

No study has been reported yet on the efficacy of BA.2 CCP against other Omicron sublineages, which would be the commonest scenario if a CCP program is re-launched at this time.

Discussion

CCP with a high nAb titer is preferable, since nAbs are by definition antiviral, and there is now strong clinical evidence that nAb titers correlate with clinical benefit in randomized clinical trials (RCT)^{14,15}. Although nAb titers correlate with vaccine efficacy^{35,36}, it is important to keep in mind that SARS-CoV-2 binding non-neutralizing antibodies can similarly provide protection via Fc-mediated functions^{37,38}. However, such functions are harder to measure in the laboratory and no automated assay exist for use in clinical laboratories. Hence, whereas the presence of a high nAb titer in CCP is evidence for antibody effectiveness *in vitro*, the absence of nAb titer does not imply lack of protection *in vivo* where Fc effects mediate protection by other mechanisms such as ADCC, complement activation and phagocytosis.

The mechanism by which CCP from vaccinated COVID-19 convalescent individuals neutralizes Omicron lineage variants is probably a combination of higher amounts of antibody and broader antibody

specificity. Higher amounts of antibody could neutralize antigenically different variants through the law of mass action whereby even lower affinity antibodies elicited to earlier variants would bind to the Omicron variant as mass compensates for reduced binding strength to drive the reaction forward. In addition, vaccinated COVID-19 convalescent individuals would have experienced SARS-CoV-2 protein in two antigenically different forms: as part of intact infective virions generated *in vivo* during an infectious process and as antigens in vaccine preparations. As the immune system processes the same antigen in different forms there are numerous opportunities for processing the protein in different manners that can diversity the specificity of the immune response and thus increase the likelihood of eliciting antibodies that react with variant proteins. Structurally, it has been shown that mRNA third dose vaccination induces mostly mainly class 1/2 antibodies encoded by IGHV1-58;IGHJ3-1 and IGHV1-69;IGHJ4-1 germ lines, but not the IGHV2-5;IGHJ3-1 germline, broadly cross-reactive Class 3 antibodies seen after infection³⁹.

Our analysis provides strong evidence that, unlike what has been observed in Syrian hamster models⁴⁰, CCP from unvaccinated donors is likely (less than 50%) to have any measurable Omicron neutralization. Although the nAb GMT threshold for clinical utility remains poorly defined, it is noticeable that low Omicron nAb GMT were generally detected in CCP after infection from pre-Omicron VOCs.

On the contrary, despite the huge heterogeneity of vaccine schedules, CCP from vaccinated and COVID-19 convalescent individuals (Vax-CCP) consistently harbors high nAb titers against Omicron if collected up to 6 months since last event (either vaccine dose or infection). These Omicron neutralizing levels are comparable in dilutional titers to that of WA-1 CCP neutralizing WA-1, but their prevalence is much higher at this time, facilitating recruitment of suitable donors. Pre-Omicron CCP boosted with WA-1 type vaccines induces heterologous immunity that effectively neutralizes Omicron in the same assays which rule in or out therapeutic anti-Spike monoclonal antibodies. Consequently, prescreening of Vax-CCP donors for nAb titers is not necessary, and qualification of Vax-CCP units remains advisable only within clinical trials. A more objective way to assess previous infection (convalescence) would be measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly^{41,42}. Previous symptomatic infection and vaccination can be established by collecting past medical history (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring rapidly declining anti-N antibodies. Although there is no formal evidence for this, it is likely that asymptomatic infection (leading to lower nAb levels) also leads to lower nAb levels after vaccination compared to symptomatic infection, given that disease severity correlates with antibody titer^{43,44}; hence those asymptotically infected donors missed by investigating PMH are also less likely to be useful.

The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several authorities, including the FDA, do not currently allow collection from such donors for CCP therapy on the basis that the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior to the polyclonal anti-Spike-only response induced by vaccinees. This may be a false premise for recipients of inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, the efficacy against Omicron is largely reduced^{20,22,45}, but the impact of boost doses is still unreported at the time of writing. Table 1 and Table 9 clearly show that 3-doses of BNT162b2 are enough to restore nAb levels against Omicron in the absence of SARS-CoV-2 infection.

Another point to consider is that information on nAb levels after the third vaccine dose has been almost exclusively investigated for only 1 month of follow-up, while studies on convalescents extend to more than 6 months: to date it seems hence advisable to start from convalescent vaccinees rather than uninfected 3-dose vaccinees. This is also confirmed by immune escape reported *in vivo* after usage of vaccine (non-convalescent) plasma⁴⁶ despite very high nAb titres, likely due to restricted antigen specificity. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than the approved, short schedules⁴⁷⁻⁵⁰, but this remain to be confirmed in larger series. The same is true for breakthrough infections from Alpha or Delta VOC in fully BNT162b2 vaccinated subjects⁵¹, although variation in time from infection due to successive waves is a major confounder.

With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins collected from regular donors could become a more standardized alternative to CCP, but their efficacy to date (at the peak of the vaccinations campaign) is still 16-fold reduced against Omicron compared to wild-type SARS-CoV-2, and such preparations include only IgG and not IgM and IgA, which have powerful SARS-CoV-2 activity.

CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one would prefer RCT evidence of efficacy against Omicron before deployment, there is concern that variants are generated so rapidly that by the time such trials commenced this variant could be replaced for another. Given the success of CCP in 2 outpatient RCTs reducing hospitalization^{14,15} and the loss of major mAb therapies due to Omicron antigenic changes, the high titers in CCP collected from vaccinated convalescents provides an immediate option for COVID-19, especially in LMIC. Given the reduced hospitalization rate with Omicron compared to Delta^{52,53}, it is even more relevant to identify patient subsets at risk of progression in order to minimize the number needed to treat to prevent a single hospitalization: moving from the same criteria used for mAb therapies while using the same (now unused) in-hospital facilities seems a logical approach.

We declare we have no conflict of interest related to this manuscript.

References

1. Yeh, T.-Y. & Contreras, G.P. Tajima D test accurately forecasts Omicron / COVID-19 outbreak. 2021.2012.2002.21267185 (2021).
2. Ahmed, S.F., Quadeer, A.A. & McKay, M. SARS-CoV-2 T cell responses are expected to remain robust against Omicron. 2021.2012.2012.472315 (2021).
3. Bernasconi, A., *et al.* Report on Omicron Spike mutations on epitopes and immunological/epidemiological/kinetics effects from literature. (2021).
4. Cao, Y.R., *et al.* B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. 2021.2012.2007.470392 (2021).
5. Planas, D., *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* **602**, 671-675 (2022).
6. Liu, L., *et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. *Nature* **602**, 676-681 (2022).

- 285 7. Aggarwal, A., *et al.* SARS-CoV-2 Omicron: reduction of potent humoral responses and
286 resistance to clinical immunotherapeutics relative to viral variants of concern.
287 2021.2012.2014.21267772 (2021).
- 288 8. VanBlargan, L.A., *et al.* An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes
289 neutralization by several therapeutic monoclonal antibodies. 2021.2012.2015.472828
290 (2021).
- 291 9. Carreno, J.M., *et al.* Activity of convalescent and vaccine serum against a B.1.1.529 variant
292 SARS-CoV-2 isolate. 2021.2012.2020.21268134 (2021).
- 293 10. Zhou, S., *et al.* β -d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But
294 Is Also Mutagenic To Mammalian Cells. *The Journal of Infectious Diseases* **224**, 415-419
295 (2021).
- 296 11. Jayk Bernal, A., *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized
297 Patients. *N Engl J Med* **386**, 509-520 (2022).
- 298 12. Gupta, K., Strymish, J., Stack, G. & Charness, M. Rapid Relapse of Symptomatic SARS-CoV-2
299 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. Accessed online at
300 <https://www.researchsquare.com/article/rs-1588371/v1> on May 1, 2022. *Research Square*
301 (2022).
- 302 13. Focosi, D., *et al.* COVID-19 convalescent plasma and randomized clinical trials: rebuilding
303 confidence by explaining failures and finding signals of efficacy. 2021.2009.2007.21263194
304 (2021).
- 305 14. Libster, R., *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
306 *N Engl J Med* **384**, 610-618 (2021).
- 307 15. Sullivan, D., *et al.* Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl*
308 *J Med* (2021).
- 309 16. Vickers, M.A., *et al.* Exponential increase in neutralizing and spike specific antibodies
310 following vaccination of COVID-19 convalescent plasma donors. *Transfusion* **61**, 2099-2106
311 (2021).
- 312 17. Schmidt, F., *et al.* High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody
313 escape. *Nature* (2021).
- 314 18. Germanio, C.D., *et al.* Vaccination of COVID-19 Convalescent Plasma Donors Increases
315 Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants. 2021.2010.2028.21265622
316 (2021).
- 317 19. Jacobsen, H., *et al.* Diminished neutralization responses towards SARS-CoV-2 Omicron VoC
318 after mRNA or vector-based COVID-19 vaccinations. 2021.2012.2021.21267898 (2021).
- 319 20. Zhao, X., *et al.* Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and
320 protein subunit vaccines and the convalescents. 2021.2012.2016.472391 (2021).
- 321 21. Dolzhikova, I.V., *et al.* Sputnik Light booster after Sputnik V vaccination induces robust
322 neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant.
323 2021.2012.2017.21267976 (2021).
- 324 22. Bowen, J.E., *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive
325 panel of human vaccines. 2022.2003.2015.484542 (2022).
- 326 23. Carazo, S., *et al.* Protection against Omicron re-infection conferred by prior heterologous
327 SARS-CoV-2 infection, with and without mRNA vaccination. 2022.2004.2029.22274455
328 (2022).
- 329 24. Iketani, S., *et al.* Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages.
330 2022.2002.2007.479306 (2022).
- 331 25. Tjan, L.H., *et al.* High neutralizing activity against Omicron BA.2 can be induced by COVID-19
332 mRNA booster vaccination. 2022.2004.2019.22273940 (2022).
- 333 26. Zhou, R., *et al.* Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits
334 broadly cross-reactive immune responses. 2021.2012.2027.474218 (2021).

- 335 27. Bekliz, M., *et al.* Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma,
336 Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through
337 homologous and heterologous variants. 2021.2012.2028.21268491 (2021).
- 338 28. Turelli, P., *et al.* Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing
339 activity. 2022.2005.2002.22274436 (2022).
- 340 29. Yu, J., *et al.* Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.
341 2022.2002.2006.22270533 (2022).
- 342 30. Seaman, M.S., *et al.* Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron
343 (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses.
344 2022.2003.2002.22271731 (2022).
- 345 31. Zou, J., *et al.* Cross neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
346 2022.2003.2030.486409 (2022).
- 347 32. Park, Y.-J., *et al.* Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
348 2022.2005.2008.491108 (2022).
- 349 33. Cao, Y.R., *et al.* BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
350 2022.2004.2030.489997 (2022).
- 351 34. Khan, K., *et al.* Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing
352 immunity. 2022.2004.2029.22274477 (2022).
- 353 35. Khoury, D.S., *et al.* Neutralizing antibody levels are highly predictive of immune protection
354 from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
- 355 36. Feng, S., *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2
356 infection. *Nat Med* **27**, 2032-2040 (2021).
- 357 37. Gilbert, P.B., *et al.* Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy
358 clinical trial. *Science*, eab3435 (2021).
- 359 38. Earle, K.A., *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines.
360 *Vaccine* **39**, 4423-4428 (2021).
- 361 39. Andreano, E., *et al.* COVID-19 mRNA third dose induces a unique hybrid immunity-like
362 antibody response. 2022.2005.2009.491201 (2022).
- 363 40. Ryan, K.A., *et al.* Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from
364 disease caused by the Omicron variant. 2021.2012.2024.474081 (2021).
- 365 41. Krutikov, M., *et al.* Prevalence and duration of detectable SARS-CoV-2 nucleocapsid
366 antibodies in staff and residents of long-term care facilities over the first year of the
367 pandemic (VIVALDI study): prospective cohort study in England. *The Lancet Healthy*
368 *Longevity* (2021).
- 369 42. Amjadi, M.F., *et al.* Anti-membrane and anti-spike antibodies are long-lasting and together
370 discriminate between past COVID-19 infection and vaccination. 2021.2011.2002.21265750
371 (2021).
- 372 43. Klein, S., *et al.* Sex, age, and hospitalization drive antibody responses in a COVID-19
373 convalescent plasma donor population. in *medRxiv [Preprint]* 2020.2006.2026.20139063
374 (2020).
- 375 44. Focosi, D. & Franchini, M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in
376 COVID-19 convalescents: Implications for convalescent plasma donor recruitment. *European*
377 *journal of haematology* **107**, 24-28 (2021).
- 378 45. Yu, X., *et al.* Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from
379 neutralization induced by a third booster dose of vaccination. 2021.2012.2017.21267961
380 (2021).
- 381 46. Gachoud, D., *et al.* Antibody response and intra-host viral evolution after plasma therapy in
382 COVID-19 patients pre-exposed or not to B-cell depleting agents. 2022.2004.2024.22274200
383 (2022).

- 384 47. Chatterjee, D., *et al.* SARS-CoV-2 Omicron Spike recognition by plasma from individuals
385 receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell Rep* **38**,
386 110429 (2022).
- 387 48. Grunau, B., *et al.* Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.
388 *Jama* (2021).
- 389 49. Tauzin, A., *et al.* A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector
390 functions and boost pre-existing humoral and T cell responses. *medRxiv [Preprint]*,
391 2021.2003.2018.435972 (2021).
- 392 50. Skowronski, D.M., *et al.* Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules
393 and extended dosing intervals: test-negative design studies from British Columbia and
394 Quebec, Canada. 2021.2010.2026.21265397 (2021).
- 395 51. Miyamoto, S., *et al.* Vaccination-infection interval determines cross-neutralization potency
396 to SARS-CoV-2 Omicron after breakthrough infection by other variants.
397 2021.2012.2028.21268481 (2022).
- 398 52. León, G., *et al.* Development and pre-clinical characterization of two therapeutic equine
399 formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.
400 *medRxiv [Preprint]*, 2020.2010.2017.343863 (2020).
- 401 53. Wolter, N., *et al.* Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant
402 in South Africa. 2021.2012.2021.21268116 (2021).
- 403 54. Zeng, C., *et al.* Neutralization and Stability of SARS-CoV-2 Omicron Variant. *bioRxiv* (2021).
- 404 55. Lechmere, T., *et al.* Broad Neutralization of SARS-CoV-2 Variants, Including Omicron,
405 following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. *mBio* **13**,
406 e0379821 (2022).
- 407 56. Schmidt, F., *et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med*
408 **386**, 599-601 (2022).
- 409 57. Arien, K.K., *et al.* Three doses of BNT162b2 vaccine confer neutralising antibody capacity
410 against the SARS-CoV-2 Omicron variant. *NPJ Vaccines* **7**, 35 (2022).
- 411 58. Lusvardi, S., *et al.* SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum,
412 but evades most convalescent serum and therapeutic antibodies. *Sci Transl Med*, eabn8543
413 (2022).
- 414 59. Hoffmann, M., *et al.* The Omicron variant is highly resistant against antibody-mediated
415 neutralization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447-456 e411
416 (2022).
- 417 60. Zou, J., *et al.* Neutralization against Omicron SARS-CoV-2 from previous non-Omicron
418 infection. *Nat Commun* **13**, 852 (2022).
- 419 61. Zhang, L., *et al.* The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
420 *Emerging microbes & infections* **11**, 1-5 (2022).
- 421 62. Gruell, H., *et al.* mRNA booster immunization elicits potent neutralizing serum activity
422 against the SARS-CoV-2 Omicron variant. *Nat Med* **28**, 477-480 (2022).
- 423 63. Dejnirattisai, W., *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from
424 neutralizing antibody responses. *Cell* **185**, 467-484 e415 (2022).
- 425 64. Sheward, D.J., *et al.* Variable loss of antibody potency against SARS-CoV-2 B.1.1.529
426 (Omicron). *bioRxiv*, 2021.2012.2019.473354 (2021).
- 427 65. Rossler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 Omicron Variant
428 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med* **386**, 698-
429 700 (2022).
- 430 66. Tada, T., *et al.* Increased resistance of SARS-CoV-2 Omicron variant to neutralization by
431 vaccine-elicited and therapeutic antibodies. *EBioMedicine* **78**, 103944 (2022).

- 432 67. Aggarwal, A., *et al.* SARS-CoV-2 Omicron: evasion of potent humoral responses and
433 resistance to clinical immunotherapeutics relative to viral variants of concern. *medRxiv*,
434 2021.2012.2014.21267772 (2021).
- 435 68. Zhao, X., *et al.* Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.
436 *N Engl J Med* **386**, 894-896 (2022).
- 437 69. Bowen, J.E., *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive
438 panel of human vaccines. *bioRxiv* (2022).
- 439 70. Carreno, J.M., *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
440 *Nature* **602**, 682-688 (2022).
- 441 71. Syed, A.M., *et al.* Omicron mutations enhance infectivity and reduce antibody neutralization
442 of SARS-CoV-2 virus-like particles. *medRxiv* (2022).
- 443 72. Haveri, A., *et al.* Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA
444 vaccination in health care workers and elderly subjects. *Eur J Immunol* (2022).
- 445 73. Li, M., *et al.* Convalescent plasma with a high level of virus-specific antibody effectively
446 neutralizes SARS-CoV-2 variants of concern. *Blood advances*, 2022.2003.2001.22271662
447 (2022).
- 448 74. Kurahashi, Y., *et al.* Cross-neutralizing activity against Omicron could be obtained in SARS-
449 CoV-2 convalescent patients who received two doses of mRNA vaccination. *medRxiv*,
450 2022.2002.2024.22271262 (2022).
- 451 75. Edara, V.V., *et al.* mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing
452 activity against the SARS-CoV-2 omicron variant. *Cell Rep Med* **3**, 100529 (2022).
- 453 76. Muik, A., *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited
454 human sera. *Science (New York, N. Y.)* **375**, 678-680 (2022).
- 455 77. Cele, S., *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
456 *Nature* **602**, 654-656 (2022).
- 457 78. Wilhelm, A., *et al.* Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera
458 and Monoclonal Antibodies. *medRxiv*, 2021.2012.2007.21267432 (2021).
- 459 79. Doria-Rose, N.A., *et al.* Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron
460 Neutralization. *medRxiv*, 2021.2012.2015.21267805 (2021).
- 461 80. Kawaoka, Y., *et al.* Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
462 *Res Sq* (2022).
- 463 81. Dejnirattisai, W., *et al.* Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by
464 post-immunisation serum. 2021.2012.2010.21267534 (2021).

465
466

Figure 1

PRISMA flowchart for the current study.




Figure 2

GMT of nAb's against WA-1 versus Omicron by study. Mean entire study neutralization of WA-1 in filled circles with Omicron in empty circles with means and fold reduction above data and number of studies above x-axis. All means are not statistically significant in difference by multiple comparison in Tukey's test.




Figure 3

Percent of individual plasma samples in each study showing any titer of Omicron neutralization. The percent of samples within a study condition which neutralized Omicron graphed in increasing percentages with the number of samples tested on the right y axis. A) pre-Alpha CCP neutralization of Omicron; B) Alpha, Beta and Delta CCP neutralization of Omicron C) 2 dose mRNA vaccines neutralization of Omicron D) post COVID-19/post vaccine (VaxCCP) and uninfected 3-dose vaccine neutralization of Omicron.




Figure 4

Geometric mean titers of ant-WA.1 or anti-Omicron neutralizing antibodies in plasma samples from 5 studies investigating diverse SARS-CoV-2 infecting lineage or vaccination status. 5 studies characterized A) pre-Alpha, Alpha, Beta and Delta CCP for Omicron nAb compared to WA-1, and also B) 2 or 3 doses BNT162b plasma, as well as post-COVID-19 plus BNT162b vaccine (VaxCCP). 9 studies looked at the same vaccine conditions comparing WA-1 nAb to Omicron nAb.




Table 1

Comparison of WA-1 to Omicron nAb and percent with any Omicron nAb amongst VOC CCP and vaccination status.

plasma type	number of studies	WA-1 nAb GMT	fold reduction in nAb GMT vs. Omicron	Omicron nAb GMT	total number individuals in all studies	total Omicron neutralizing number	Omicron neutralizing percent
pre-Alpha	27	851	31	31	679	300	44
Alpha	6	1,115	61	13	101	38	38
Beta	5	186	15	51	37	19	51
Delta	7	2,023	21	533	94	69	73
2 dose BNT162b2 plasma	22	1,319	35	87	434	204	47
2 dose mRNA-1273 plasma	9	1,275	39	57	134	81	60
post-COVID-19/full vacc plasma	19	28,599	19	938	305	269	88
3 dose BNT162b2 plasma	17	7,657	11	759	307	293	95

507 Table 2
508 Synopsis of *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron

reference	time	(pre-Alpha CCP) WA-1 mean	(pre-Alpha CCP) fold drop vs. Omicron	(pre-Alpha CCP) Omicron mean	(pre-Alpha CCP) number	(pre-Alpha CCP) Omicron neutralizing number	(pre-Alpha CCP) Omicron neutralizing percent
Zeng ⁵⁴		4980	177	28	18	3	17
Lechmere ⁵⁵							

509

Liu ⁶		4344	32	136	10	2	20
Schmidt ⁵⁶	1.2 mo	2616	38	69	20	19	95
Schmidt ⁵⁶	12 mo	2037	15	136	20	17	85
Schmidt ⁵⁶	6 mo	1678	49	34	20	13	65
Arien ⁵⁷		1086	22	49	10	1	10
Lusvarghi ⁵⁸		715	29	25	16	2	13
Hoffman ⁵⁹		614	80	8	17	8	47
Zou ⁶⁰		601	16	38	64	41	64
Planas ⁵	6 mo	569	20	28	16	6	38
Planas ⁵	12 mo	580	20	29	23	8	35
Zhang ⁶¹		556	8	70	28	28	100
Grueil ⁶²	1.5 mo	494	82	6	30	3	10
Grueil ⁶²	12 mo	93	12	8	30	9	30
Dejnirattisai ⁶³		475	17	28	32	32	100
Sheward ⁶⁴		300	6	50	34	25	74
Rosler ⁶⁵							
Tada ⁶⁶		233	26	9	10	4	40
Aggerwal ⁶⁷		210	21	10	20	0	0
Zhao ⁶⁸		193	17	11	16	1	6
Bowen ⁶⁹		162	16	10	28	13	46
Zou ⁶⁰		142	5	28	36	30	83
Carreno ⁷⁰		100	11	9	15	4	27
Syed ⁷¹		80	4	20	8	6	75
Bekliz ⁷²		37	45	1	34	5	15
Haveri ⁷²		32	32	1	13	0	0
Li ⁷³		28	14	2	71	5	7
Kurahashi ⁷⁴		19	13	2	40	15	38
average		851	31	31			44
total					679	300	

510

511 Table 3. Synopsis of *in vitro* studies investigating the efficacy of Alpha CCP against Omicron

reference	time	(Alpha CCP) WA-1 mean	(Alpha CCP) fold drop vs. Omicron	(Alpha CCP) omicron mean	(Alpha CCP) number	(Alpha CCP) Omicron neutralizing number	(Alpha CCP) Omicron neutralizing percent
Lusvarghi ⁵⁸		4978	166	30	4	1	25
Dejnirattisai ⁶³		1313	34	39	18	18	100
Rosler ⁶⁵		260	64	4	10	0	0
Haveri ⁷²		64	32	2	20	0	0
Bekliz ²⁷		45	56	1	12	2	17
Li ⁷³		28	14	2	37	17	46
average		1115	61	13			38
total					101	38	

512

513

514 Table 4. Synopsis of *in vitro* studies investigating the efficacy of Beta CCP against Omicron.

reference	time	(beta CCP) WA-1 mean	(beta CCP) fold drop vs. omicron	(beta CCP) omicron mean	(beta CCP) number	(beta CCP) omicron neutralizing number	(beta CCP) omicron neutralizing percent
Lusvarghi ⁵⁸		439	2	220	2	2	100
Dejnirattisai ⁶³		327	12	28	14	14	100
Rosler ⁶⁵		128	32	4	8	1	13
Bekiz ²⁷		21	23	1	8	2	25
Haveri ⁷²		17	8	2	5	0	0
Average		186	15	51			51
Total					37	19	

515

516 Table 5. Synopsis of *in vitro* studies investigating the efficacy of Delta CCP against Omicron.

reference	time	(Delta CCP) WA-1 mean	(Delta CCP) fold drop vs. omicron	(Delta CCP) Omicron mean	(Delta CCP) number	(Delta CCP) Omicron neutralizing number	(Delta CCP) Omicron neutralizing percent
Zeng ⁵⁴		11200	3	3733	19	10	53
Lechmere ⁵⁵		4751	28	170	14	12	86
Lusvarghi ⁵⁸		1211	66	18	15	12	80
Aggerwal ⁶⁷		770	21	37	10	9	90
Rosler ⁶⁵		192	25	8	7	1	14
Bekiz ²⁷		72	24	3	10	6	60
Dejnirattisai ⁶³		47	2	27	19	19	100
Average		2023	21	533			73
Total					94	69	

517

Table 6. Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron.

reference	time	(2 dose BNT162b2 plasma) WA-1 mean	(2 dose BNT162b2 plasma) fold drop vs. Omicron	(2 dose BNT162b2 plasma) Omicron mean	(2 dose BNT162b2 plasma) number	(2 dose BNT162b2 plasma) Omicron neutralizing number	(2 dose BNT162b2 plasma) Omicron neutralizing percent
Schmidt ⁵⁶	1 mo	7627	83	92	18	15	83
Liu ⁶		4669	21	222	13	6	46
Zeng ⁵⁴		2769	23	120	48	13	27
Schmidt ⁵⁶	5 mo	2435	19	128	18	15	83
Dejnirattisai ⁶³		1993	105	19	20	20	100
Chatterjee ⁴⁷		1544	2	935	25	25	100
Syed ⁷¹		1280	16	80	21	14	67
Tada ⁶⁶		859	34	25	9	7	78
Bowen ⁶⁹		764	27	28	10	9	90
Chatterjee ⁴⁷		641	6	105	19	10	53
Hoffman ⁵⁹	3 mo	604	60	10	11	1	9
Lusvarghi ⁵⁸		562	26	22	39	3	8
Gruell ⁶²	1 mo	546	68	8	30	10	33
Rosler ⁶⁵	1 mo	512	32	16	20	9	45
Edara ⁷⁵	1 mo	384	19	20	13	2	15
Muik ⁷⁶		368	61	6	25	8	32
Cele ⁷⁷		359	19	19	8	7	88
Bekliz ²⁷		338	86	4	16	11	69
Planas ⁵	5 mo	329	11	30	16	1	6
Carreno ⁷⁰		300	23	13	10	7	70
Gruell ⁶²	5 mo	139	15	9	30	11	37
Wilheim ⁷⁸		6	11	1	15	0	0
Average		1319	35	87			47
Total					1319	35	

521 Table 7. Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2
522 mRNA-1273 doses against Omicron.

reference	time	(2 dose mRNA- 1273 plasma) WA-1 mean	(2 dose mRNA- 1273 plasma) fold drop vs. Omicron	(2 dose mRNA- 1273 plasma) Omicron mean	(2 dose mRNA- 1273 plasma) number	(2 dose mRNA-1273 plasma) Omicron neutralizing number	(2 dose mRNA-1273 plasma) Omicron neutralizing percent
Doria- Rose ⁷⁹		3016	48	63	30	22	73
Syed ⁷¹		2560	8	320	10	8	80
Doria- Rose ⁷⁹		2269	84	27	30	22	73
Bowen ⁶⁹		1155	32	36	11	9	82
Tada ⁶⁶		999	26	38	8	5	63
Edara ⁷⁵	1 mo	745	50	15	11	4	36
Carreno ⁷⁰		400	43	9	10	10	100
Rosler ⁶⁵	5 mo	320	40	8	10	1	10
Wilhelm ⁷⁸		10	20	1	14	0	0
Average		1275	39	57			60
Total					134	81	

523

524 Table 8. Synopsis of *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2
525 BNT162b2 doses) subjects (VaxCCP) against Omicron.

reference	month post vacc	(post- COVID- 19/full vacc plasma) WA-1 mean	(post- COVID- 19/full vacc plasma) fold drop vs. Omicron	(post- COVID- 19/full vacc plasma) Omicron mean	(post- COVID- 19/full vacc plasma) number	(post-COVID- 19/full vacc plasma) Omicron neutralizing number	(post-COVID- 19/full vacc plasma) Omicron neutralizing percent
Schmidt ⁵⁶		388872	48	8102	17	17	100
Planas ⁵		78162	53	1475	22	22	100
Tada ⁶⁶		14868	16	929	7	7	100
Cele ⁷⁷		13333	25	533	13	13	100
Kawoaka ⁸⁰		10863	16	665	5	5	100
Kawoaka ⁸⁰		10002	7	1369	13	13	100
Lechmere ⁵⁵		8843	5	1769	15	15	100
Gruehl ⁶²		7997	5	1599	30	30	100
Arien ⁵⁷		4822	20	241	10	10	100
Carreno ⁷⁰		3000	14	214	10	10	100
Dejnirattisai ⁶³		1899	9	215	17	17	100
Li ⁷³		1598	20	80	20	20	100
Bekliz ²⁷		1190	18	66	6	6	100
Haveri ⁷²		1024	32	32	33	33	100
Rosler ⁶⁵		1000	4	250	5	5	100
Edara ⁷⁵		625	20	31	24	15	63
Kurahashi ⁷⁴	12 mo	369	7	51	19	19	100
Wilheim ⁷⁸		200	32	6	20	5	25
Kurahashi ⁷⁴	1 mo	22	14	2	19	7	37
average		28599	19	938			88
total					305	269	

526

527 Table 9. Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects
528 vaccinated with 3 BNT162b2 doses against Omicron.

reference	time	(3 dose BNT162b2 plasma) WA-1 mean	(3 dose BNT162b2 plasma) fold drop vs. Omicron	(3 dose BNT162b2 plasma) Omicron mean	(3 dose BNT162b2 plasma) number	(3 dose BNT162b2 plasma) Omicron neutralizing number	(3 dose BNT162b2 plasma) Omicron neutralizing percent
Schmidt ⁵⁶	1 mo	65617	17	3860	18	18	100
Planas ⁵		12739	18	708	20	20	100
Zeng ⁵⁴		10412	3	3155	23	20	87
Dejnirattisai ⁶³		9219	14	649	20	20	100
Gruehl ⁶²	1 mo	6241	5	1248	30	30	100
Lusvarghi ⁵⁸		5029	7	718	39	39	100
Tada ⁶⁶		4892	14	349	12	12	100
Liu ⁶		4673	7	668	15	15	100
Kawoaka ⁸⁰		2866	6	485	10	10	100
Arien ⁵⁷		2157	13	166	10	10	100
Hoffman ⁵⁹	1 mo	2006	7	287	10	9	90
Edara ⁷⁵		1247	14	89	35	31	89
Carreno ⁷⁰		1000	8	125	10	10	100
Syed ⁷¹		960	4	240	8	8	100
Muik ⁷⁶		673	6	112	28	27	96
Haveri ⁷²		290	12	24	7	7	100
Wilheim ⁷⁸	0.5 mo	150	37	4	12	7	58
average		7657	11	759			95
total					307	293	

529

530

531 Table 10. Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects
 532 vaccinated with 3 mRNA-1273, AZD-1222 or Ad26.COV2 doses against Omicron.

533

reference	vaccine type	WA-1 mean	fold drop vs. Omicron	Omicron mean	number	Omicron neutralizing number	Omicron neutralizing percent
Careno ⁷⁰	COVID19 + mRNA-1273	3000	11	272	10	10	100
Edara ⁷⁵	COVID19 + mRNA-1273 6 mo	931	25	38	13	9	69
Careno ⁷⁰	3 dose mRNA-1273	1000	17	60	10	10	100
Doria-Rose ⁷⁹	3 dose mRNA-1273	8457	4	2002	30	30	100
Doria-Rose ⁷⁹	3 dose mRNA-1273	4216	6	650	30	30	100
Edara ⁷⁵	3 dose mRNA-1273	1395	15	96	17	16	94
Dejnirattisai ⁸¹	AZD1222	390	19	21	41	41	100
Rossler ⁶⁵	AZD1222	250	25	10.0	20	0	0
Planas ⁵	AZD1222 5 mo	187	18	10	18	2	10
Syed ⁷¹	Ad26.COV2	28	1	20.0	9	2	22
Schmidt ⁵⁶	Ad26.COV2 1 mo	588	24	25	19	2	11
Schmidt ⁵⁶	Ad26.COV2 6 mo	982	23	43	19	11	58

534